Stay updated on Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedThe footer revision label changed from v3.8.0 to v3.8.1, with no apparent change to the study details.SummaryDifference0.0%

- Check10 days agoChange DetectedThe ClinicalTrials.gov record is displayed instead of a 403 Forbidden page, with the study overview, eligibility criteria, treatment arms, outcomes, locations, and other record details.SummaryDifference100%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check31 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check38 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2; the study page continues to display a 403 error.SummaryDifference0.2%

- Check45 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

Stay in the know with updates to Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial page.